Effects of Pre-emptive Scalp Infiltration With Low-dose Ketorolac and Ropivacaine for Postoperative Pain (PAINLESS)
Primary Purpose
Pain, Supratentorial Brain Tumor
Status
Unknown status
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Ketorolac
Ropivacaine
Epinephrine
Sponsored by
About this trial
This is an interventional prevention trial for Pain focused on measuring Pre-emptive Scalp Infiltration, Ketorolac, Postoperative Pain, Supratentorial Craniotomy, A pilot Study
Eligibility Criteria
Inclusion Criteria:
- Scheduled for elective supratentorial tumour resection;
- Planned general anaesthesia;
- American Society of Anesthesiologists (ASA) physical status I - II;
- Age ranging from 18 to 65 years old;
- Participates required to fix their head in a head clamp intraoperatively;
- Participates with an anticipated awake within 2 hours after surgery.
Exclusion Criteria:
- Allergy/intolerance to study drugs including anesthetic drugs, ketorolac and epinephrine;
- Expected delayed extubation or no plan to extubate;
- History of neurosurgeries;
- Long-term use of analgesics and sedatives (more than 2 weeks)
- Receiving any painkiller within 24 h before the operation;
- Extreme body mass index (BMI) (less than 15 or more than 35);
- Patients with impaired cardiopulmonary;
- Patients with impaired renal function;
- Patients with impaired hepatic function;
- History of chronic headache;
- Patients with cognitive deficit;
- Patients with intellectual disability;
- Patients with uncontrolled epilepsy;
- Patients with psychiatric disorders;
- Difficulties in using PCA device
- Difficulties in understanding the use of numeral rating scale (NRS) ;
- Patients with suspected intracranial hypertension;
- Pregnant or at breastfeeding;
- Infection at the incisional site;
- History of radiation therapy and chemotherapy preoperatively
- With great likelihood of postoperative radiation therapy and chemotherapy based on preoperative imaging.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
The ketorolac group
The control group
Arm Description
Patients assigned to the ketorolac group will receive pre-emptive scalp infiltration with 30ml of local infiltration solution containing 60 mg ropivacaine, 6 mg ketorolac and 0.1mg epinephrine.
In the control group, preoperative peri-incisional scalpinfiltration will be performed using 30ml of 60 mgropivacaine and 0.1mg epinephrine.
Outcomes
Primary Outcome Measures
cumulative doses of patient-controlled analgesia (PCA) sufentanil consumption
cumulative doses of patient-controlled analgesia (PCA) butorphanol consumption from 0 to 48 h postoperatively The primary outcome measure will be cumulative doses of PCA butorphanol consumption from 0 to 48 h postoperatively
Secondary Outcome Measures
The time to first request for PCA sufentanil
The time to first request for patient-controlled analgesia
frequency of pressing PCA pump
frequency of pressing PCA pump
numeral rating scale (NRS) Score
0 for"no pain" and 10 for "pain as severe as you can imagine"
Pain control satisfaction score (PCSS) postoperatively
0 for unsatisfactory and 10 for very satisfactory
Ramsay sedation score (RSS)
1: Anxious, agitated, restless; Ramsey 2: Cooperative, oriented, tranquil; Ramsey 3: Responsive to commands only If Asleep; Ramsey 4: Brisk response to light glabellar tap or loud auditory stimulus; Ramsey 5: Sluggish response to lightglabellar tap or loud auditory stimulus; Ramsey 6: No response to light glabellar tap or loud auditory stimulus.Asleep; Ramsey 4: Brisk response to light glabellar tap or loud auditory stimulus; Ramsey 5: Sluggish response to lightglabellar tap or loud auditory stimulus; Ramsey 6: No response to light glabellar tap or loud auditory stimulus.
pulse oxygen saturation(SpO2)
mean arterial blood pressure(MAP)
heart rate(HR)
respiratory rate(RR)
Length of hospital stay
postoperative nausea and vomiting(PONV)
The presence of respiratory depression
respiratory rate <10 breaths per minute or SpO2 was<90 %
The incidence of haematoma, wound infection or gastric ulcers
side effects
Full Information
NCT ID
NCT04380298
First Posted
May 5, 2020
Last Updated
September 7, 2020
Sponsor
Beijing Tiantan Hospital
1. Study Identification
Unique Protocol Identification Number
NCT04380298
Brief Title
Effects of Pre-emptive Scalp Infiltration With Low-dose Ketorolac and Ropivacaine for Postoperative Pain
Acronym
PAINLESS
Official Title
Effects of Pre-emptive Scalp Infiltration With Low-dose Ketorolac and Ropivacaine for Postoperative Pain Relief After Elective Supratentorial Craniotomy (PAINLESS): a Randomized Controlled Pilot Trial
Study Type
Interventional
2. Study Status
Record Verification Date
September 2020
Overall Recruitment Status
Unknown status
Study Start Date
December 1, 2020 (Anticipated)
Primary Completion Date
July 31, 2021 (Anticipated)
Study Completion Date
August 31, 2021 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Beijing Tiantan Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The PAINLESS study is a single-center, prospective, randomized, open-label, blinded-endpoint (PROBE) controlled clinical pilot study to compare the efficacy and safety of pre-emptive scalp infiltration with ropivacaine plus ketorolac and ropivacaine alone for postoperative pain relief in adults undergoing elective supratentorial craniotomies.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pain, Supratentorial Brain Tumor
Keywords
Pre-emptive Scalp Infiltration, Ketorolac, Postoperative Pain, Supratentorial Craniotomy, A pilot Study
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
40 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
The ketorolac group
Arm Type
Experimental
Arm Description
Patients assigned to the ketorolac group will receive pre-emptive scalp infiltration with 30ml of local infiltration solution containing 60 mg ropivacaine, 6 mg ketorolac and 0.1mg epinephrine.
Arm Title
The control group
Arm Type
Active Comparator
Arm Description
In the control group, preoperative peri-incisional scalpinfiltration will be performed using 30ml of 60 mgropivacaine and 0.1mg epinephrine.
Intervention Type
Drug
Intervention Name(s)
Ketorolac
Intervention Description
30ml of local infiltration solution containing 60mg ropivacaine
Intervention Type
Drug
Intervention Name(s)
Ropivacaine
Intervention Description
30ml of local infiltration solution containing 6mg ketorolac
Intervention Type
Drug
Intervention Name(s)
Epinephrine
Intervention Description
30ml of local infiltration solution containing 0.1mg epinephrine
Primary Outcome Measure Information:
Title
cumulative doses of patient-controlled analgesia (PCA) sufentanil consumption
Description
cumulative doses of patient-controlled analgesia (PCA) butorphanol consumption from 0 to 48 h postoperatively The primary outcome measure will be cumulative doses of PCA butorphanol consumption from 0 to 48 h postoperatively
Time Frame
0 to 48 hours postoperatively
Secondary Outcome Measure Information:
Title
The time to first request for PCA sufentanil
Description
The time to first request for patient-controlled analgesia
Time Frame
0 to 48 hours postoperatively
Title
frequency of pressing PCA pump
Description
frequency of pressing PCA pump
Time Frame
Within 48hours postoperatively
Title
numeral rating scale (NRS) Score
Description
0 for"no pain" and 10 for "pain as severe as you can imagine"
Time Frame
at 2 hours, 4 hours, 8 hours, 24 hours, 48 hours postoperatively
Title
Pain control satisfaction score (PCSS) postoperatively
Description
0 for unsatisfactory and 10 for very satisfactory
Time Frame
at 24 hours and 48 hours post-operation
Title
Ramsay sedation score (RSS)
Description
1: Anxious, agitated, restless; Ramsey 2: Cooperative, oriented, tranquil; Ramsey 3: Responsive to commands only If Asleep; Ramsey 4: Brisk response to light glabellar tap or loud auditory stimulus; Ramsey 5: Sluggish response to lightglabellar tap or loud auditory stimulus; Ramsey 6: No response to light glabellar tap or loud auditory stimulus.Asleep; Ramsey 4: Brisk response to light glabellar tap or loud auditory stimulus; Ramsey 5: Sluggish response to lightglabellar tap or loud auditory stimulus; Ramsey 6: No response to light glabellar tap or loud auditory stimulus.
Time Frame
at 2 hours, 4 hours, 8 hours, 24 hours and 48 hours postoperatively
Title
pulse oxygen saturation(SpO2)
Time Frame
1 minutes before anesthesia induction, 1 minutes after anesthesia induction, 1 minutes after scalp infiltration, at the beginning of skull drilling, mater cutting and skin closure and at 2hours, 4 hours, 8 hours , 24 hours and 48 hours postoperatively
Title
mean arterial blood pressure(MAP)
Time Frame
1 minutes before anesthesia induction, 1 minutes after anesthesia induction, 1 minutes after scalp infiltration, at the beginning of skull drilling, mater cutting and skin closure and at 2hours, 4 hours, 8 hours , 24 hours and 48 hours postoperatively
Title
heart rate(HR)
Time Frame
1 minutes before anesthesia induction, 1 minutes after anesthesia induction, 1 minutes after scalp infiltration, at the beginning of skull drilling, mater cutting and skin closure and at 2hours, 4 hours, 8 hours , 24 hours and 48 hours postoperatively
Title
respiratory rate(RR)
Time Frame
1 minutes before anesthesia induction, 1 minutes after anesthesia induction, 1 minutes after scalp infiltration, at the beginning of skull drilling, mater cutting and skin closure and at 2hours, 4 hours, 8 hours , 24 hours and 48 hours postope
Title
Length of hospital stay
Time Frame
Length of hospital stay, an arverage of 2 weeks
Title
postoperative nausea and vomiting(PONV)
Time Frame
within 48 hours postoperatively
Title
The presence of respiratory depression
Description
respiratory rate <10 breaths per minute or SpO2 was<90 %
Time Frame
within 48 hours postoperatively
Title
The incidence of haematoma, wound infection or gastric ulcers
Description
side effects
Time Frame
during hospitalization, within 2 weeks postoperatively
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Scheduled for elective supratentorial tumour resection;
Planned general anaesthesia;
American Society of Anesthesiologists (ASA) physical status I - II;
Age ranging from 18 to 65 years old;
Participates required to fix their head in a head clamp intraoperatively;
Participates with an anticipated awake within 2 hours after surgery.
Exclusion Criteria:
Allergy/intolerance to study drugs including anesthetic drugs, ketorolac and epinephrine;
Expected delayed extubation or no plan to extubate;
History of neurosurgeries;
Long-term use of analgesics and sedatives (more than 2 weeks)
Receiving any painkiller within 24 h before the operation;
Extreme body mass index (BMI) (less than 15 or more than 35);
Patients with impaired cardiopulmonary;
Patients with impaired renal function;
Patients with impaired hepatic function;
History of chronic headache;
Patients with cognitive deficit;
Patients with intellectual disability;
Patients with uncontrolled epilepsy;
Patients with psychiatric disorders;
Difficulties in using PCA device
Difficulties in understanding the use of numeral rating scale (NRS) ;
Patients with suspected intracranial hypertension;
Pregnant or at breastfeeding;
Infection at the incisional site;
History of radiation therapy and chemotherapy preoperatively
With great likelihood of postoperative radiation therapy and chemotherapy based on preoperative imaging.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Fang Luo, M.D
Phone
+8613611326978
Email
13611326978@163.com
First Name & Middle Initial & Last Name or Official Title & Degree
Yitong Jia, M.D
Phone
+8613811109032
Email
13811109032@163.com
12. IPD Sharing Statement
Plan to Share IPD
Yes
Citations:
PubMed Identifier
25845547
Citation
Song J, Li L, Yu P, Gao T, Liu K. Preemptive scalp infiltration with 0.5% ropivacaine and 1% lidocaine reduces postoperative pain after craniotomy. Acta Neurochir (Wien). 2015 Jun;157(6):993-8. doi: 10.1007/s00701-015-2394-8. Epub 2015 Apr 7.
Results Reference
background
PubMed Identifier
18484242
Citation
Kerr DR, Kohan L. Local infiltration analgesia: a technique for the control of acute postoperative pain following knee and hip surgery: a case study of 325 patients. Acta Orthop. 2008 Apr;79(2):174-83. doi: 10.1080/17453670710014950.
Results Reference
background
PubMed Identifier
25238439
Citation
Niemelainen M, Kalliovalkama J, Aho AJ, Moilanen T, Eskelinen A. Single periarticular local infiltration analgesia reduces opiate consumption until 48 hours after total knee arthroplasty. A randomized placebo-controlled trial involving 56 patients. Acta Orthop. 2014 Dec;85(6):614-9. doi: 10.3109/17453674.2014.961399. Epub 2014 Sep 19.
Results Reference
background
PubMed Identifier
23514638
Citation
Andersen KV, Nikolajsen L, Haraldsted V, Odgaard A, Soballe K. Local infiltration analgesia for total knee arthroplasty: should ketorolac be added? Br J Anaesth. 2013 Aug;111(2):242-8. doi: 10.1093/bja/aet030. Epub 2013 Mar 20.
Results Reference
background
Learn more about this trial
Effects of Pre-emptive Scalp Infiltration With Low-dose Ketorolac and Ropivacaine for Postoperative Pain
We'll reach out to this number within 24 hrs